Pliant Therapeutics
PLRX
86 hedge funds and large institutions have $54.8M invested in Pliant Therapeutics in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 13 closing their positions.
2.56% less ownership
Funds ownership: 80.24% → 77.68% (-2.6%)
5% less funds holding
Funds holding: 91 → 86 (-5)
12% less capital invested
Capital invested by funds: $62.5M → $54.8M (-$7.65M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
53% less call options, than puts
Call options by funds: $80K | Put options by funds: $172K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.56M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.19M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.22M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$369K |
| 5 |
Renaissance Technologies
New York
|
+$240K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.74M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.32M |
| 3 |
Millennium Management
New York
|
-$756K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$592K |
| 5 |
CC
Centiva Capital
New York
|
-$545K |
PLRX Hedge Fund Activity: Q2 2026 in Review
86 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2026, worth a combined $54.8M — down 12% from $62.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PLRX and 9 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 18 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $3.56M. The largest seller was Blue Owl Capital Holdings, exiting entirely with an estimated $3.74M sold.
- 86 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2026, down from 91 in Q1 2026.
- Funds reported $54.8M of Pliant Therapeutics stock for Q2 2026, down 12% quarter-over-quarter.
- 9 funds opened new Pliant Therapeutics positions in Q2 2026 and 13 closed out, a net change of -4 holders.
- The largest Pliant Therapeutics buyer in Q2 2026 was ADAR1 Capital Management, an estimated $3.56M added.
- The largest Pliant Therapeutics seller in Q2 2026 was Blue Owl Capital Holdings, an estimated $3.74M sold.
Based on aggregated 13F filings for Q2 2026.